Full-Time
SAP Analytics Cloud & Datasphere Consultant
Posted on 9/23/2025
AstraZeneca
10,001+ employees
Global pharmaceutical company developing prescription medicines
No salary listed
Chennai, Tamil Nadu, India
Hybrid
Minimum of three days per week in-office.
 Data & Analytics (2) |
|---|
| , |
- Degree in Computer Science, Business Informatics or a comparable degree.
- Overall, 8-12 years of experience and at least 2-3 years’ experience working on SAP SAC / Datasphere solutions as a Consultant, Analyst, Developer or relevant role.
- Demonstrable experience designing and implementing solutions applying SAC for planning, forecasting, and KPI reporting, as well as integrating with SAP Datasphere and upstream processes.
- Expertise with SAC predictive functionality, Sensible features (Hard-working Assist, Hard-working Predict, Sensible Discovery), advanced story canvases, data blending, cross-calculations, input controls, and linked analysis.
- Skilled in connecting SAC and Datasphere to varied data sources, including SAP HANA, and external databases.
- Proficiency in SAP Datasphere for building unified, harmonized, and governed data models to serve enterprise analytics.
- In-depth understanding of data integration and ETL processes across SAC, Datasphere, and other analytics platforms.
- Advanced scripting abilities in SQL, Python, and JavaScript to enable data manipulation and automation within both SAC and Datasphere environments.
- Experience with SAC scripting for creating custom widgets and analytics applications, as well as automating data flows in Datasphere.
- Understanding of SAP related Finance and/or Operations processes will be valued.
- Certification in one or more of the following will be appreciated: SAC Data Analyst, Data Engineer, Low-Code/No-Code Developer.
- Good communication skills and ability to work in an Agile environment.
- Energetic, organised and self-motivated.
- Fluent in business English.
- Design and develop analytic applications using SAP Analytics Cloud (SAC) and SAP Datasphere, focusing on critical metric and analytical models that support strategic business initiatives.
- Build interactive dashboards and critical metric applications in SAC for both import and live scenarios, demonstrating data sourced from SAP Datasphere and other platforms.
- Create scalable, secure, and governed data models in SAP Datasphere to support advanced analytics and reporting use cases.
- Integrate SAC dashboards seamlessly with SAP Datasphere datasets, ensuring up-to-date and consistent analytics for end users.
- Use predictive scenarios, R-visualizations, and external libraries to create immersive and insightful user experiences in both SAC and Datasphere environments.
- Continuously optimize dashboard and application performance across SAC and Datasphere, while providing recommendations for enhancements and identifying bottlenecks.
- Develop and document Business Objects Universes, reports, and dashboards, ensuring accuracy and alignment with enterprise data standards.
- Connect, model, and harmonize data from SAP and non-SAP sources in Datasphere, facilitating cross-system analytics through SAC.
- Design comprehensive reports with multiple tabs, queries, visualizations, and drill-down capabilities tailored to business requirements.
- Apply standard methodologies in data visualization and user experience, enhancing accessibility and adoption of solutions built on SAC and Datasphere.
- Demonstrate expertise in data integration, connectivity, and modelling across SAC, Datasphere, and other data platforms.
- Apply strong analytical and problem-solving skills to address technical challenges and drive continuous performance improvement.
- Provide technical leadership, coaching, and mentorship to team members, fostering knowledge growth in SAC and Datasphere technologies.
- Establish and maintain standard processes for software quality, documentation, and project delivery within agile and scrum frameworks.
- Customize SAC applications using scripting languages (such as JavaScript) and leverage advanced features in Datasphere for data orchestration and automation.
- Collaborate with multi-functional teams, contributing to the solution design and integration of SAC and Datasphere in end-to-end business processes.
AstraZeneca develops and markets prescription medicines and vaccines for global health, focusing on oncology, cardiovascular/metabolic, respiratory, and infectious diseases. Its products work by targeting specific biological pathways or cells to treat diseases or prevent infections, using small-molecule drugs, biologics, and vaccines. The company differentiates itself through its dual heritage from Sweden and the UK, a broad pipeline, and strong R&D with collaborations to move from discovery to patient access across multiple therapeutic areas. Its goal is to improve people’s health by discovering, developing, and delivering medicines and vaccines worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Cambridge, United Kingdom
Founded
1913
Simplify's Take
What believers are saying
- Oncology sales surged 16% to $6.8B in Q1 2026.
- New Dublin API facility opened April 30, 2026, boosts manufacturing.
- £300M UK investment resumes after UK-US deal raises NICE threshold.
What critics are saying
- FDA panel rejected camizestrant May 9, 2026, derails breast cancer pipeline.
- Oncology generates 45% revenue; safety issues collapse growth trajectory.
- Trump MFN policy collapse voids UK pricing uplift, triggers capex freeze.
What makes AstraZeneca unique
- AstraZeneca formed in 1999 merger of Astra AB and Zeneca Group.
- Leads oncology with Imfinzi, Tagrisso, Enhertu driving 44% revenue.
- Certified 17,000 employees in AI for drug discovery acceleration.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Flexible Work Hours
Company News
* home * latest news * press releases * AstraZeneca announces opening of new API manufacturing facility in Dublin. AstraZeneca announces opening of new API manufacturing facility in Dublin 30/04/2026 Ireland AstraZeneca today officially opened their new Active Pharmaceutical Ingredient (API) manufacturing facility in Dublin. This new facility demonstrates how advanced automation, AI, and innovative new technologies push the boundaries of science and manufacturing. It was developed with the support and collaboration of Ireland's investment agency, IDA Ireland. Taoiseach Micheál Martin said: "Investments like this state-of-the-art new manufacturing facility strengthen our healthcare and biopharma base, support high-quality employment, and help ensure medicines can be supplied to patients around the world. It is a significant vote of confidence in Ireland's life sciences ecosystem and in the highly skilled people who work across the sector. I warmly welcome AstraZeneca's continued commitment to Dublin and I commend IDA Ireland for its ongoing work in supporting and securing investments of this scale." Pam Cheng, Executive Vice President, Global Operations, IT & Chief Sustainability Officer, AstraZeneca said: "This cutting-edge API Commercialisation facility is an innovative and unique asset in its global operations network, and plays a key role in the development and launch of its new medicines across its oncology portfolio and beyond. Through advanced automation, AI and innovative new technologies, IDA Ireland is pushing the boundaries of science and manufacturing - enhancing speed, flexibility, and sustainability to deliver future therapies to patients. Thank you to all colleagues and partners for making this milestone a reality." Michael Lohan, CEO of IDA Ireland said: "Healthcare and biopharma remain a key growth driver within IDA Ireland's strategy, and investments like this new API facility underline Ireland's strength in advanced manufacturing, innovation and talent. We are delighted to support AstraZeneca as it continues to expand its operations in Dublin, creating high-value jobs and strengthening the resilience of global supply chains while delivering life-changing medicines for patients worldwide." You might also be interested in. West continues its investment in Ireland with Dublin manufacturing facility expansion. West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced an additional 330 roles as part of an expansion of its manufacturing site in Damastown, Dublin. West is supported by the Irish Government, through IDA Ireland. Novartis and Deciphex host roundtable about Ireland's AI sector to mark collaboration. Collaboration Between Novartis and Deciphex Harnesses AI For Drug Discovery and Development.
Ailux appoints Maria Belvisi, Ph.D., as Chief Scientific Officer. Apr 09, 2026, 20:00 ET * Professor Belvisi joins from AstraZeneca, where she served as Senior Vice President, Research & Development, Respiratory & Immunology and built one of the most productive early R&D organizations in global pharma, including leading tozorakimab from preclinical research through Phase 3 investment decision - a program that recently delivered landmark wins in two pivotal COPD trials * Her appointment accelerates Ailux's evolution from AI-native biologics discovery into a fully integrated drug development organization, targeting first clinical entry by 2027 * Professor Belvisi will lead Ailux's scientific strategy and new program development, and will establish and lead a UK research site to complement Ailux's Shanghai research capabilities. SHANGHAI and LONDON, April 9, 2026 /PRNewswire/ - Ailux, an AI-native biotech company discovering and engineering next-generation biologics across multiple indications, today announced the appointment of Maria G. Belvisi, Ph.D. as Chief Scientific Officer. Professor Belvisi brings more than three decades of industry and academic leadership in drug research and development, including nearly a decade at AstraZeneca where she served as Senior Vice President, Research and Development, Respiratory & Immunology, BioPharmaceuticals R&D. She will report to Alex Li, Chief Executive Officer of Ailux. Ailux is an AI-native biotech company headquartered in Shanghai, founded within and wholly-owned by XtalPi (2228.HK), a global leader in building the AI & robotics infrastructure for life sciences and beyond. Ailux combines proprietary AI biologics platforms with a 30,000 square foot wet lab and a global team of approximately 150 across China, the UK, and the US. Ailux has collaborated with Eli Lilly, Johnson & Johnson, and UCB, and is advancing its internal pipeline toward first clinical entry by 2027. Professor Belvisi joined AstraZeneca in 2017 and was accountable for the global Respiratory & Immunology R&D organization spanning approximately 500 scientists across the UK, Sweden, the US, and Spain. During her tenure she built and advanced one of the industry's most innovative and productive early R&I portfolios, with end-to-end responsibility from target identification through Phase 3 investment decisions. Most recently, tozorakimab - a potential first-in-class IL-33 antibody that she championed from early preclinical development through the Phase 3 investment decision - met its primary endpoints in both the OBERON and TITANIA trials in COPD. The results, announced last month, have been widely recognized as landmark for the field and potentially transformational for COPD patients. Alongside her industry career, Maria has held a professorship at the National Heart & Lung Institute, Imperial College London - a position she continues to hold today. During her time leading the Imperial research group, she trained more than thirty PhD students and published over 250 peer-reviewed papers. She also served as Research Director of the European Respiratory Society (2013-2016) and founded IR Pharma, a contract research organization serving major pharmaceutical companies in the respiratory space. In her new role at Ailux, Maria will also establish and lead a UK research site, further expanding the company's presence in one of the world's leading centers for biomedical research and innovation. She is a Fellow of the European Respiratory Society, the British Pharmacological Society, and the Academy of Medical Sciences, and was named one of Endpoints News' "20 Outstanding Women in Biopharma" in 2021. "Maria is exactly the kind of scientific leader Ailux needs at this stage of our journey," said Alex Li, CEO of Ailux. "She has spent her career turning bold scientific hypotheses into medicines that reach patients - building programs from scratch, taking them through the clinic, and doing so at a scale that few have matched. We are building Ailux to go the full distance, and Maria's scientific leadership will be central to every step of that journey." "What drew me to Ailux is the genuine integration of AI and biology - not AI as a tool applied to conventional drug discovery, but as a co-equal foundation for how programs are conceived and built," said Professor Belvisi, CSO of Ailux. "I believe Ailux's platform and team give us a real opportunity to originate first-in-class and best-in-class medicines, and I am excited to join the team and work together to build a global company that can deliver transformative therapies to patients." About Ailux Ailux is an AI-native biotech company headquartered in Shanghai and a wholly-owned subsidiary of XtalPi (2228.HK), a global leader in building the AI & robotics infrastructure for life sciences and beyond. Established as an independent operation five years ago with its own dedicated team, platforms, and pipeline, Ailux combines proprietary AI biologics platforms with a 30,000 square foot wet lab to discover and engineer next-generation biologics across multiple therapeutic areas. The company's global team of approximately 150 spans China, the UK, and the US, drawing on the distinct strengths of each geography. Ailux has collaborated with Eli Lilly, Johnson & Johnson, and UCB, and is now advancing its own pipeline with the first programs expected to enter clinical development by 2027. SOURCE Ailux
IDEAYA Biosciences (NASDAQ: IDYA) teams with AstraZeneca on ide849-imfinzi SCLC trial. Filing Impact (Moderate) Filing Sentiment Rhea-AI Filing summary. IDEAYA Biosciences entered a clinical collaboration with AstraZeneca to test IDEAYA's investigational DLL3 TOP1 antibody-drug conjugate IDE849 together with AstraZeneca's PD-L1 inhibitor Imfinzi in extensive-stage small cell lung cancer. IDEAYA will sponsor the combination study, while AstraZeneca supplies Imfinzi. IDEAYA is running a multi-site global Phase 1 clinical trial of IDE849 in DLL3 upregulated solid tumors, including small cell lung cancer, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma, reflecting significant unmet medical need and the potential of DLL3 as a targeted therapy approach. 8-K event classification. Item 8.01 - Other Events Key terms. clinical collaboration agreement, antibody-drug conjugate, Phase 1 clinical trial, programmed death-ligand 1 (PD-L1) inhibitor, +2 more 04/09/2026 - 06:01 AM Faq. What clinical collaboration did IDEAYA Biosciences (IDYA) announce with AstraZeneca? IDEAYA Biosciences entered a clinical collaboration agreement with AstraZeneca to study IDE849 with AstraZeneca's Imfinzi in extensive-stage small cell lung cancer. IDEAYA will sponsor the combination trial, while AstraZeneca will supply Imfinzi, aiming to evaluate safety and efficacy in this difficult-to-treat cancer. What is IDE849 in the IDEAYA Biosciences (IDYA) and AstraZeneca study? IDE849 is IDEAYA Biosciences' investigational, potential first-in-class DLL3 TOP1 antibody-drug conjugate. It targets DLL3, which is reported to be upregulated in several solid tumor types, and is being evaluated for safety and efficacy in a global Phase 1 clinical trial program. Which cancers are targeted in IDEAYA Biosciences' IDE849 Phase 1 trial? The IDE849 Phase 1 trial focuses on DLL3 upregulated solid tumors, including extensive-stage small cell lung cancer, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma. These cancers have significant unmet medical need, and DLL3's limited expression in normal tissues makes it a promising therapeutic target. Who sponsors and supplies drugs in the IDEAYA (IDYA) and AstraZeneca collaboration? IDEAYA Biosciences will sponsor the clinical combination study evaluating IDE849 with AstraZeneca's Imfinzi. AstraZeneca will supply Imfinzi, a PD-L1 inhibitor, for the trial. This structure lets IDEAYA lead study operations while leveraging AstraZeneca's established immunotherapy agent. Where will IDEAYA Biosciences' IDE849 clinical trial enroll patients? IDEAYA's multi-site global Phase 1 clinical trial for IDE849 plans to enroll patients across North America, Europe, Australia, South America, and Asia. This broad geographic footprint is designed to access diverse patient populations with DLL3 upregulated solid tumors, including small cell lung cancer. Filing exhibits & attachments. 3 documents
Result of AGM. 9 April 2026 Results of Annual General Meeting held on 9 April 2026 AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 10 - 13 were passed as special resolutions; all other resolutions were passed as ordinary resolutions. | / | Resolution | Votes for | % of votes cast | Votes against | % of votes cast | Votes cast in total | Total votes cast as a % of issued share capital | Votes withheld | | 1 | To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2025 | 1,198,663,815 | 99.99% | 166,701 | 0.01% | 1,198,830,516 | 77.29% | 2,309,793 | | 2 | To confirm the 2025 interim dividends | 1,199,596,253 | 99.91% | 1,054,621 | 0.09% | 1,200,650,874 | 77.41% | 489,438 | | 3 | To appoint KPMG LLP as Auditor | 1,200,331,533 | 99.98% | 203,239 | 0.02% | 1,200,534,772 | 77.40% | 605,649 | | 4 | To authorise the Directors to agree the remuneration of the Auditor | 1,200,231,237 | 99.98% | 277,426 | 0.02% | 1,200,508,663 | 77.40% | 631,646 | | 5a | To re-elect Michel Demaré as a Director | 1,181,183,631 | 98.39% | 19,312,258 | 1.61% | 1,200,495,889 | 77.40% | 644,420 | | 5b | To re-elect Pascal Soriot as a Director | 1,188,466,505 | 99.00% | 12,056,196 | 1.00% | 1,200,522,701 | 77.40% | 617,611 | | 5c | To re-elect Aradhana Sarin as a Director | 1,191,427,943 | 99.30% | 8,391,362 | 0.70% | 1,199,819,305 | 77.36% | 1,321,004 | | 5d | To re-elect Philip Broadley as a Director | 1,171,470,116 | 97.59% | 28,983,447 | 2.41% | 1,200,453,563 | 77.40% | 686,746 | | 5e | To re-elect Euan Ashley as a Director | 1,197,441,098 | 99.75% | 3,022,489 | 0.25% | 1,200,463,587 | 77.40% | 676,722 | | 5f | To re-elect Birgit Conix as a Director | 1,200,028,460 | 99.96% | 428,931 | 0.04% | 1,200,457,391 | 77.40% | 683,030 | | 5g | To re-elect Rene Haas as a Director | 1,176,085,879 | 97.97% | 24,361,879 | 2.03% | 1,200,447,758 | 77.40% | 692,663 | | 5h | To re-elect Karen Knudsen as a Director | 1,200,091,469 | 99.97% | 370,843 | 0.03% | 1,200,462,312 | 77.40% | 678,109 | | 5i | To re-elect Diana Layfield as a Director | 1,199,711,377 | 99.94% | 755,622 | 0.06% | 1,200,466,999 | 77.40% | 673,422 | | 5j | To re-elect Anna Manz as a Director | 1,199,171,542 | 99.89% | 1,310,287 | 0.11% | 1,200,481,829 | 77.40% | 658,592 | | 5k | To re-elect Sheri McCoy as a Director | 1,181,129,650 | 98.39% | 19,334,808 | 1.61% | 1,200,464,458 | 77.40% | 675,963 | | 5l | To re-elect Tony Mok as a Director | 1,197,756,109 | 99.77% | 2,702,422 | 0.23% | 1,200,458,531 | 77.40% | 681,890 | | 5m | To re-elect Marcus Wallenberg as a Director | 993,713,162 | 83.80% | 192,121,282 | 16.20% | 1,185,834,444 | 76.46% | 15,305,980 | | 6 | To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2025 | 1,161,885,452 | 96.78% | 38,608,771 | 3.22% | 1,200,494,223 | 77.40% | 646,086 | | 7 | To renew the authorisation to grant awards under the French Appendix 3 of the AstraZeneca Performance Share Plan 2020 | 1,186,833,063 | 98.89% | 13,376,194 | 1.11% | 1,200,209,257 | 77.38% | 930,948 | | 8 | To authorise limited political donations | 1,176,818,096 | 98.50% | 17,954,803 | 1.50% | 1,194,772,899 | 77.03% | 6,367,525 | | 9 | To authorise the Directors to allot shares | 1,115,450,202 | 92.92% | 84,989,076 | 7.08% | 1,200,439,278 | 77.40% | 701,146 | | 10 | To authorise the Directors to disapply pre-emption rights | 1,113,184,536 | 92.75% | 87,024,695 | 7.25% | 1,200,209,231 | 77.38% | 930,073 | | 11 | To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments | 1,053,612,673 | 87.78% | 146,670,037 | 12.22% | 1,200,282,710 | 77.39% | 856,594 | | 12 | To authorise the Company to purchase its own shares | 1,197,748,658 | 99.81% | 2,335,330 | 0.19% | 1,200,083,988 | 77.38% | 1,056,436 | | 13 | To reduce the notice period for general meetings | 1,108,104,727 | 92.31% | 92,307,790 | 7.69% | 1,200,412,517 | 77.40% | 727,904 | Nazneen Rahman retired from the Board at the conclusion of the AGM. For the purposes of section 430(2B) of the Companies Act 2006, she will receive her pro-rata entitlement to non-executive director fees for the month of April 2026. No other remuneration payment or payment for loss of office will be made. A copy of the resolutions passed at the AGM (other than resolutions concerning ordinary business) has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism. Issued capital As at 7 April 2026, the number of issued shares of the Company was 1,550,988,781 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held. AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca Matthew Bowden Company Secretary AstraZeneca PLC This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
New Virginia economic laws: Gov. Spanberger signs legislation on development projects. By: WTVR CBS 6 Web Staff Posted 12:27 PM, Apr 06, 2026 RICHMOND, Va. - Gov. Abigail Spanberger has signed another batch of legislation into Virginia law, the most recent bills focusing on economic development in the Commonwealth. A news release from the governor's office says the bills passed with bipartisan support and will bring 3,250 jobs to Virginia. "From my very first day in office, I have been working to create a stable business environment so companies can hire, expand, and continue to invest in our Commonwealth," said Gov. Spanberger. "I am signing these bills into law so we can continue to grow Virginia's economy and create opportunities for Virginians." The following bills focus on economic development: * HB1531 (Delegate Luke Torian), SB835 (Senator L. Louise Lucas) - Avio USA will invest more than $537 million and create more than 1,500 jobs in Pittsylvania, building solid rocket motors for the defense, tactile propulsion, missile systems, and commercial space sectors. * HB799 (Delegate Luke Torian), SB403 (Senator L. Louise Lucas) - Hitachi Energy will invest more than $457 million and create more than 825 jobs in Halifax to produce critical electrical grid infrastructure. * HB800 (Delegate Luke Torian), SB404 (Senator L. Louise Lucas) - Eli Lilly and Company will invest more than $2 billion and create more than 450 jobs in Goochland to manufacture active pharmaceutical ingredients for cancer, autoimmune, and other advanced therapies. * HB1076 (Delegate Amy Laufer), SB527 (Senator Creigh Deeds) - AstraZeneca will invest $4 billion and create 500 jobs in Albermarle to manufacture medication for chronic diseases and antibody-drug conjugates. "Attracting new businesses and jobs to Virginia is a core focus of my administration," Spanberger said. "I'm proud of the hundreds of millions of dollars in investment we have already announced this year. I look forward to continuing to work with legislators, local communities, and business leaders as we make clear that Virginia is the top state in the nation to grow or start a business." CBS 6 is committed to sharing community voices on this important topic. Email your thoughts to the CBS 6 Newsroom. : CONNECT WITH US